SCHEMBL4692961

SCHEMBL4692961

CSCCN1C(=O)C(Cl)=C(c2ccccc2)C1=O

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAD51 Q06609 1/20 0.41
NR1H2 P55055 7/20 0.41
NR1H3 Q13133 7/20 0.41
LCK P06239 1/20 0.40
SMN1; SMN2 Q16637 3/20 0.40
RAB9A P51151 2/20 0.40
NPC1 O15118 1/20 0.40
CASP3 P42574 1/20 0.40
SENP8 Q96LD8 1/20 0.40
SENP7 Q9BQF6 1/20 0.40
SENP6 Q9GZR1 1/20 0.40
MAPT P10636 3/20 0.37
ALDH1A1 P00352 1/20 0.37
PABPC1 P11940 1/20 0.37
KDM4E B2RXH2 2/20 0.37
NPSR1 Q6W5P4 1/20 0.37
TP53 P04637 1/20 0.36
HPGD P15428 1/20 0.36
MAPK1 P28482 1/20 0.36
PTGS2 P35354 2/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4685924 0.80 NPC1 (0.46) RAD51NR1H2NR1H3LCKSMN1; SMN2
SCHEMBL4685918 0.79 NR1H2 (0.60) RAD51NR1H2NR1H3LCKMAPT
SCHEMBL4685696 0.79 ALDH1A1 (0.43) RAD51NR1H2NR1H3LCKSMN1; SMN2
SCHEMBL4688655 0.77 MEN1 (0.44) RAD51NR1H2NR1H3LCKSMN1; SMN2
SCHEMBL1307183 0.73 NPC1 (0.62) SMN1; SMN2RAB9ANPC1CASP3SENP8
SCHEMBL15451446 0.73 NR1H2 (0.56) RAD51NR1H2NR1H3CASP3HPGD
SCHEMBL6310937 0.72 LCK (0.57) NR1H2NR1H3LCKSMN1; SMN2RAB9A
SCHEMBL4688716 0.72 NR1H2 (0.72) NR1H2NR1H3SMN1; SMN2MAPTALDH1A1
SCHEMBL6427000 0.70 NR1H2 (0.60) RAD51NR1H2NR1H3SMN1; SMN2MAPT
SCHEMBL4693182 0.70 NR1H2 (0.48) RAD51NR1H2NR1H3SMN1; SMN2RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7432288-B2 Pyrrole-2,5-dione derivatives as Liver X receptor modulators ASTRAZENECA AB (SE) 2008-10-07 US disclosed
EP-1646626-B1 PYRROLE-2, 5-DIONE DERIVATIVES AS LIVER X RECEPTOR MODULATORS ASTRAZENECA AB (SE) 2008-07-02 EP disclosed
US-20060235015-A1 Pyrrole-2,5-dione derivatives as liver x receptor modulators ASTRAZENECA AB (SE) 2006-10-19 US disclosed
EP-1646626-A1 PYRROLE-2, 5-DIONE DERIVATIVES AS LIVER X RECEPTOR MODULATORS AstraZeneca AB (SE) 2006-04-19 EP disclosed
WO-2005005417-A1 PYRROLE-2, 5-DIONE DERIVATIVES AS LIVER X RECEPTOR MODULATORS ASTRAZENECA AB (SE) 2005-01-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060235015-A1 Pyrrole-2,5-dione derivatives as liver x receptor modulators NR1H2, NR1H3, SREBF2 RAD51 4519/4885NR1H2 1/4885NR1H3 2/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.